Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2026-04-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 6 pages 319.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report & Appendix 4C' and includes detailed operational and financial information for the quarter ended 31 March 2026 (Q3 FY26). It contains a narrative on business activities, clinical development updates, strategic partnerships, and a detailed cash flow statement (Appendix 4C) with operating, investing, and financing cash flows. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). It is not a simple announcement of report publication, nor is it a certification or regulatory filing. Therefore, the document fits best under the Interim / Quarterly Report (IR) category. Q3 2026
2026-04-28 English
FDA confirms path to DEP HER2 first-in-human study 3 pages 193.5KB
Regulatory Filings Classification · 85% confidence The document is a corporate announcement (an ASX Announcement) regarding FDA feedback on the company’s clinical development strategy for its DEP® HER2 candidate. It does not present financial results, fundraising activity, corporate governance changes, or an investor slide deck. It is a regulatory disclosure-type announcement without fitting any of the specific categories like earnings release, M&A, or board changes. Therefore it falls under the general regulatory announcements fallback category (RNS).
2026-04-20 English
Becoming a substantial holder 2 pages 180.0KB
Regulatory Filings
2026-04-14 English
Application for quotation of securities - SPL 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme related). It is not a financial report, earnings release, or management discussion, but rather a formal announcement related to capital changes and securities quotation on the exchange. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the actual announcement, not just a brief notice or report publication announcement.
2026-04-06 English
Ceasing to be a substantial holder 3 pages 144.1KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of ceasing to be a substantial holder' and references Corporations Law Section 671B and Form 605, which are regulatory filings related to changes in substantial shareholdings. It details changes in relevant interests of UBS Group AG and its related bodies corporate in the voting securities of STARPHARMA HOLDINGS LIMITED, including dates and transaction details. The document does not contain financial statements, management discussion, or other report content but is a formal notification of shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length (8829 characters) supports it being a detailed notification rather than a brief announcement or a full report.
2026-03-11 English
Becoming a substantial holder 7 pages 241.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under Corporations Law Section 671B. It details the substantial shareholding of UBS Group AG and its related bodies corporate in Starpharma Holdings Limited, including voting power, relevant interests, registered holders, consideration paid, and associates. The document is a regulatory disclosure about changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document length is substantial and contains detailed shareholding data, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2026-03-02 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.